Vaccines with Virus Like Particle from FMDV A/Arg/2001 serotype and Immunostimulant Particle Adjuvant induce protection

MIGNAQUI, ANA CLARA; GAMMELLA, MARIELA; MONGINI, CLAUDIA; MARCIPAR, IVAN; BIDART, JUAN ESTEBAN; LUPI, GIULIANA; LANGELLOTTI, CECILIA; WIGDOROVITZ, ANDRES; KORNUTA, CLAUDIA; SORIA, IVANA; QUATTROCCHI, VALERIA; ZAMORANO, PATRICIA

Bangkok

Encuentro; GFRA Scientific Meeting 2019; 2019

Global Foot-and-Mouth Disease Research Alliance

Foot and Mouth Disease is an acute disease caused by Foot and Mouth Disease Virus (FMDV) which produces important economy losses. Currently available vaccines are based on inactivated FMDV. The use of Virus Like Particle (VLP) or empty capsids as a subunit vaccine has been reported to be a promising candidate because it avoids the use of virus in vaccine production and conserves the conformational viral epitopes. Serotype A/Arg/2001 VLPs obtained in mammalian cells by transient transfection were used. The murine model predicts the FMD-vaccines´ quality in cattle. New cage-like particle or Immunostimulant Particle Adjuvant (ISPA) are lipid boxes formulated with dipalmitoyl-phosphatidylcholine, cholesterol, steralamine and QuilA.In this report, the vaccine VLPs with ISPA as adjuvant was evaluated in the murine model.BALB/c mice (n=5 per group) were vaccinated with VLPs; VLPs+ISPA; VLPs+ISA206 (commercial adjuvant); ISPA alone; PBS or Commercial Vaccine. The groups were immunized on days 0 and 21, and challenged with infective virus at 36 dpv.A dose of 0.5g VLPs/vaccine was chosen because elicited the protection in 40% of animals against the viral challengeAt 36 dpv, when mice were challenged with infective FMDV A/Arg/A2001, 100% of mice vaccinated with VLPS+ISPA, VLPs+ISA206 or Commercial vaccine were protected and only 40% in VLPs alone group. At this time, when the Ab against FMDV were mesured by ELISA in Liquid Phase, the titers were: 1.00±0.01; 2.7±0.2; 2.3±0.3; 2.7±0.3 in VLPs, VLPs+ISPA, VLPs+ISA206 and commercial vaccine groups respectively. The inclusion of adjuvant in VLP vaccines, induced Abs levels significantly superior to VLP vaccines without adjuvants (p˂0.001) and similar to the commercial vaccineOn the other hand, when the antibodies were measured by Sandwich Elisa, VLPs+ISPA and VLPs+ISA206 groups presented FMDV-Ab titers: 5.1±0.2 and 4.9±0.2 higher than VLPs (2.7±0.5) (p